Foreomics Launches First Tool Predicting Mortality and Illness Risks

Foreomics, a Spanish preventive healthcare company, has developed the first scientific tool capable of predicting mortality and serious illness risks using a retrospective algorithm. This technology allows for personalized preventive and treatment actions to be anticipated, combining clinical, genetic , and medical imaging data with scientific rigor and proven clinical evidence.

Founded by Jorge García, an entrepreneur and executive in the financial insurance sector (former CEO of the Santander banking and insurance operator), and Dr. Eliseo Vañó, medical director of the CT and MRI service at Ntra. Sra. del Rosario Hospital in Madrid.

Foreomics, which has a panel of internationally renowned physicians and an independent management team, has developed this project with the aim of democratizing access to personalized prevention, generating a prediction tool that until now was only available to experimental research or highly specialized projects.

Foreomics system combines data from low-dose CT, blood tests, genetics, and lifestyle habits to produce personalized reports

In the words of Eliseo Vañó, co-founder and prominent Spanish radiologist, “the project arose after the impact that the diagnosis of a cancer had on our immediate community, where we began to investigate and found that traditional medical prediction methods are not sufficient to identify early real risks of mortality or serious illness.”

For Jorge García, “We have been able to conceptualize a model based on retrospective genetic information, which is not only based on clinical data and genetic testing, thus increasing its effectiveness and improving its conclusions. Thanks to the management team and the experience of the entire medical team behind Foreomics, we have achieved the goal of bringing this tool to market.”

The platform will be available in Spain in 2026 and plans to expand to Latin America, the United States, and Europe in 2027-2028.

Foreomics has developed a retrospective algorithm, based on thousands of real-life cases and clinical evidence, that integrates accessible data from low-dose CT scans, blood tests, genetics, and lifestyle habits, as well as a simple questionnaire. Once validated as a medical device, it will soon be marketed directly. This combination will make it possible to generate much more accurate predictions and offer each user a personalized report detailing their risk level for the main causes of mortality, providing prevention and follow-up recommendations tailored to their profile.

High multisectoral impact

The company, with an estimated pre-money value of €20 million in its most recent transaction, was founded with the goal of transforming risk management across numerous sectors: public and private hospitals, insurance companies, financial institutions, the sports sector, and citizens, consolidating Spain as a global leader in healthcare innovation.

Foreomics indicates that it has a panel of internationally renowned experts in cardiology, oncology, radiology and genetics such as José Luis Zamorano , head of Cardiology at the Ramón y Cajal Hospital; Sergio Vañó , clinical research coordinator of the Dermatology Service at the Ramón y Cajal University Hospital; Julio Mayol , director of the Innovation Unit of the San Carlos Health Research Institute; Pablo Lapunzina , coordinator of the Institute of Medical and Molecular Genetics (Ingemm) at La Paz University Hospital; and Mariano Provencio, head of Oncology at Puerta de Hierro University Hospital.

“Foreomics aims to bring a disruptive tool to society, one that until now has been out of reach for the general population. Our goal is to save lives through early prediction, democratizing prevention and placing Spain at the forefront of preventative healthcare worldwide,” explains Jorge García, co-founder of Foreomics.

For his part, Dr. Eliseo Vañó adds that “Foreomics’ strength lies in the fact that it will be the first scientifically validated solution capable of anticipating major risks of mortality and serious illness in healthy individuals. Thanks to our retrospective approach and the integration of clinical, imaging, and genetic data, we will offer accurate and applicable predictions in real life, something that other tools could not guarantee, both for individuals and companies in different sectors.”

__

(Featured image by National Cancer Institute via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in iSanidad. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.